Clinical trials: Cyclophosphamide, completed
Idiopathic Nephrotic Syndrome
Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children
Idiopathic nephrotic syndrome is steroid-sensitive in more than 90% of cases in children. However 60% of cases are steroid dependent and required treatment with immunosuppressive agent.
- Trial name
- NEPHROMYCY (NCT01092962)
- Testing
- Cyclophosphamide, Mycophenolate mofetil
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00066482
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 98 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- Children's Oncology Group
Leukemia, Myelodysplastic Syndrome
Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen
1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2.
- Trial name
- BuCyvsBUFlu (NCT00774280)
- Testing
- BuCy vs BuFlu
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Cooperative Study Group A for Hematology
Lymphoma
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Trial name
- NCT00002941
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 69 people
- Sponsor
- Children's Oncology Group
Acute Myelogenous Leukemia
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia…
- Trial name
- NCT02395822
- Testing
- IL-15
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphocytic Leukemia
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of…
- Trial name
- NCT00772486
- Testing
- ISF35
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Memgen, LLC
Conventional Chondrosarcoma, Myxoid Liposarcoma
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease…
- Conditions
- Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
- Trial name
- NCT02821507
- Testing
- sirolimus and cyclophosphamide
- Where
- 7 sites in Netherlands, Spain
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Multiple Sclerosis
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
- Trial name
- NCT00273364
- Testing
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Northwestern University
Adenocarcinoma of the Prostate
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
- Trial name
- DRibble (NCT02234921)
- Testing
- Cyclophosphamide, DRibble Vaccine, HPV Vaccinations
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UbiVac
Breast Cancer
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
This trial will evaluate the effectiveness of standard adjuvant treatment with CMF chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer who are 65 years of age and older or are poor…
- Trial name
- NCT00193011
- Testing
- Docetaxel, Cyclophosphamide, Methotrexate
- Volunteers
- 150 people
- Sponsor
- SCRI Development Innovations, LLC
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine…
- Trial name
- NCT02596971
- Testing
- Atezolizumab, Bendamustine, Cyclophosphamide
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Vasculitis, Wegener's Granulomatosis
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
The aim of this trial is to lower the morbidity rate in elderly patients affected with systemic necrotizing vasculitides, by reducing mortality and improving global outcome.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome
- Trial name
- CORTAGE (NCT00307671)
- Testing
- prednisone, methylprednisolone,cyclophosphamides, Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, Mycophenolate mofetil,methotrexate
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma
Haploidentical NK Cell Infusion in Malignant Melanoma
We hypothesized that haploidentical NK cells kill tumor cells more efficiently than autologous NK cells, based on the missing-self hypothesis.
- Trial name
- NCT00846833
- Testing
- Haploidentical NK cell
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Sarcoma
MRI Sarcoma Non Invasive Thermometry
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Using MRI to measure heat may help to determine the effectiveness of hyperthermia therapy.
- Trial name
- NCT00093509
- Testing
- doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mark Dewhirst
Peripheral T-cell Lymphomas (PTCL), PTCL-NOS
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose…
- Conditions
- Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), ALK- Anaplastic Large Cell Lymphoma (ALCL)
- Trial name
- FIL_PTCL13 (NCT02223208)
- Testing
- Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II)
- Where
- 27 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
HIV-related Lymphoma, HIV Infections
High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk
The purpose of the study is to evaluate the efficacy of an intensified first-line treatment, with conventional chemotherapy (CHOP) plus monoclonal antibody anti CD20, followed by high dose chemotherapy and PBSC transplantation in…
- Trial name
- HDT-HIV (NCT01045889)
- Testing
- Rituximab and CHOP regimen + PBSCT
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Carcinoma, Non-Small-Cell Lung
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
This is a multicentre, open-label, uncontrolled, Phase Ib clinical study. Patients who give informed consent will be screened for the study, including genotyping of the tumour and baseline characteristics.
- Trial name
- EPICAL (NCT03623750)
- Testing
- EGFR-TK Inhibitor, EGF-PTI, Cyclophosphamide
- Where
- 4 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Instituto Oncológico Dr Rosell
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin, HIV Infections
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
To determine the toxicity and effectiveness of adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination (methotrexate, bleomycin, doxorubicin…
- Trial name
- NCT00000689
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.